|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.5 HKD | -6.88% |
|
-10.03% | -29.94% |
BEIJING (Reuters) - Chinese vaccine maker CanSino Biologics Inc (CanSinoBIO) said on Friday it had returned to operating profit of 802.3 million yuan ($123.79 million) in the first six months of 2021, driven by use of its COVID-19 shot. That compared with 123.0 million yuan of operating loss in the same period a year ago, CanSinoBIO said in a filing in the Hong Kong stock exchange. It marks the first six-month profit since at least 2019. The firm is yet to achieve full-year profits since it went public in 2018 in Hong Kong.
It reported 937.1 million yuan profit and total comprehensive income for the first six months of 2021. Its single-dose COVID-19 shot, named Ad5-nCoV, has been approved for use in countries including China, Mexico, Pakistan and Chile. The vaccine approvals were one of the major drivers for the sixth-month profit, CanSinoBIO said.
($1 = 6.4813 Chinese yuan renminbi)
(Reporting by Roxanne Liu and Ryan Woo; Editing by Catherine Evans)
| 1st Jan change | Capi. | |
|---|---|---|
| -29.94% | 1.04B | |
| -5.99% | 84.46B | |
| +2.76% | 40.85B | |
| -24.88% | 27.69B | |
| +53.61% | 24.28B | |
| -8.08% | 17.09B | |
| -33.74% | 13.67B | |
| -16.63% | 11.86B | |
| -11.19% | 11.79B | |
| -2.25% | 8.07B |
CANSINO BIOLOGICS INC. 
